← Back to Search

Metabolic Imaging Agent

HP Pyruvate MRI for Cancer Detection (HC-MRI Trial)

Phase 1 & 2

Waitlist Available

Research Sponsored by University of Maryland, Baltimore

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 18-36 months

Awards & highlights

HC-MRI Trial Summary

This trial looks at using MRI imaging to detect and characterize cancer using a stable isotope of carbon. It could help detect and diagnose tumors.

Who is the study for?

This trial is for patients who already have scheduled MR imaging appointments, can safely undergo an MRI scan, and have a clinical diagnosis of a tumor. It's not open to individuals without a tumor diagnosis.Check my eligibility

What is being tested?

The study tests if hyperpolarized 13C pyruvate MRI can image various cancers by tracking the conversion of pyruvate to lactate—a process that's more active in cancer cells due to altered metabolism known as the Warburg effect.See study design

What are the potential side effects?

Since this trial involves MRI imaging with a special contrast agent (hyperpolarized 13C-Pyruvate), side effects may include discomfort at the injection site or allergic reactions, but generally, MRI is considered safe with few side effects.

HC-MRI Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 18-36 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~18-36 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and 18-36 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Pyruvate to Lactate Conversion

Secondary outcome measures

CNR

SNR

HC-MRI Trial Design

1Treatment groups

Experimental Treatment

Group I: ExperimentalExperimental Treatment1 Intervention

Participants will receive an injection of 250 mM of hyperpolarized 13-C pyruvate intravenously after standard of care imaging sequences are performed. Then participants will undergo HP-MR imaging.

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

University of Maryland, BaltimoreLead Sponsor

687 Previous Clinical Trials

374,621 Total Patients Enrolled

Media Library

Hyperpolarized 13C-Pyruvate (Metabolic Imaging Agent) Clinical Trial Eligibility Overview. Trial Name: NCT05697406 — Phase 1 & 2

Imaging Research Study Groups: Experimental

Imaging Clinical Trial 2023: Hyperpolarized 13C-Pyruvate Highlights & Side Effects. Trial Name: NCT05697406 — Phase 1 & 2

Hyperpolarized 13C-Pyruvate (Metabolic Imaging Agent) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05697406 — Phase 1 & 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are geriatric individuals being included in this trial?

"The age range for enrolment in this study is 18 to 88 years old."

Answered by AI

What characteristics make individuals ideal candidates for this research experiment?

"For this research endeavour, 25 participants aged between 18 and 88 who have existing imaging are required. Furthermore, in order to be eligible for the trial they must adhere to the following criteria: Prospects with scheduled Magnetic Resonance Imaging scans..."

Answered by AI

Could patients currently enroll in this experiment?

"According to the information hosted by clinicaltrials.gov, this specific medical trial is not presently looking for candidates; although it was first posted on February 1st 2023 and recently updated on January 20th of the same year. Not to worry though, there are 30 other trials actively recruiting right now."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

HP Pyruvate MRI in Cancers

Vikas Kundra 2024. "HP Pyruvate MRI in Cancers". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05697406.